Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY trial of antithrombotic therapy after lower-limb endovascular intervention
ISRCTN30648419Phase 4Recruiting
- Sponsor
- North Bristol NHS Trust
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of clopidogrel, aspirin and rivaroxaban in arteriosclerosis obliterans and chronic limb-threatening ischemia (CLTI) (3 arms), sponsored by North Bristol NHS Trust. Primary endpoint: Composite event-free survival. Started Jan 2025; status: recruiting.
02
Drugs
clopidogrelaspirinrivaroxaban
03
Conditions
arteriosclerosis obliteranschronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on ISRCTN30648419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN30648419.